Meddoxx Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year,
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 22.52%
- Profit Growth -21.52%
- Ebitda -14.33%
- Net Worth 28.10%
- Total Assets -2.69%
About Meddoxx Pharmaceuticals
Meddoxx Pharmaceuticals Private Limited (MPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 22 February 2014 and has a history of 11 years. Its registered office is in Kozhikode, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manojkumar Chakkiath, Vinesh Kandy, Rajeev Kolayadath, and Three other members serve as directors at the Company.
Company Details
- Location
Kozhikode, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232KL2014PTC036243
- Company No.
036243
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Meddoxx Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Kolayadath  | Managing Director | 22-Feb-2014 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manojkumar Chakkiath | Director | 05-Jun-2017 | Current |
| Vinesh Kandy | Director | 22-Feb-2014 | Current |
| Dhinkar Krishnan | Director | 22-Feb-2014 | Current |
| Manoj Nair | Director | 22-Feb-2014 | Current |
| Gopi Krishna | Director | 22-Feb-2014 | Current |
Financial Performance of Meddoxx Pharmaceuticals.
Meddoxx Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.52% increase. The company also saw a substantial fall in profitability, with a 21.52% decrease in profit. The company's net worth Soared by an impressive increase of 28.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meddoxx Pharmaceuticals?
In 2023, Meddoxx Pharmaceuticals had a promoter holding of 83.33% and a public holding of 16.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meddoxx Pharmaceuticals?
Meddoxx Pharmaceuticals has a workforce of 58 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meddoxx Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meddoxx Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
